Results of selective internal radiation therapy with SIR-Spheres for treatment of unresectable hepatocellular carcinoma

  • Thai Nguyen Van Bệnh viện Trung ương Quân đội 108
  • Ky Thai Doan Bệnh viện Trung ương Quân đội 108
  • Hung Trinh Xuan Bệnh viện Trung ương Quân đội 108
  • Tuyet Tran Thi Anh Bệnh viện Trung ương Quân đội 108
  • Giang Dinh Truong Bệnh viện Trung ương Quân đội 108
  • Lien Nguyen Thi Phuong Bệnh viện Trung ương Quân đội 108
  • Quynh Nguyen Xuan Bệnh viện Trung ương Quân đội 108
  • Trang Nguyen Thi Huyen Bệnh viện Trung ương Quân đội 108
  • Trang Ha Minh Bệnh viện Trung ương Quân đội 108
  • Thanh Tran Van Bệnh viện Trung ương Quân đội 108
  • Nga Dinh Thi Bệnh viện Trung ương Quân đội 108
  • Tien Dao Duc Bệnh viện Quân y 175
  • Thinh Nguyen Tien Bệnh viện Trung ương Quân đội 108

Main Article Content

Keywords

Hepatocellular carcinoma, selective internal radiation therapy, Yttrium 90, survival

Abstract

Objective: To evaluate the efficiency of selective internal radiation therapy (SIRT) with Y-90 microspheres and determine prognostic factors that impacts on unresectable hepatocellular carcinoma (HCC) patients. Subject and method: The data of research included 97 patients who were diagnosed with unresectable HCC and had SIRT with Y-90 resin microspheres from October 2013 to March 2019. The study was designed as retrospective investigation. The survival of patients was assessed by utilizing the Kaplan-Meier method and estimate prognostic factors that affect the survival of these patients by using Log-rank test and Cox proportional hazards Regression. Radiologic response was evaluated with the modified response evaluation criteria in solid tumors (mRECIST) criteria. Result: Ninety-seven patients (90 male, mean age 60.4 ± 12.3 years) underwent SIRT, median clinical follow-up was 16.4 (1.8 - 62) months. The median survival after SIRT was 23.9 ± 2.4 months with a 36-month survival of 39.2%. Tumor response was accorded to mRECIST criteria followed-up beyond 6 months, a complete response (CR) to treatment was observed in 12 patients (18.8%), partial response (PR) in 23 (35.8%), stable disease (SD) in 8 (12.5%) and progressive disease (PD) in 21 (32.8%). Factors associated with longer overall survival (OS) included age over 65, Barcelona-Clinic Liver Cancer (BCLC) B, tumor size larger 10cm, tumor burden more 25%, tumor response (CR/PR). On multivariate analysis, a lack of bilobar disease and tumor response (CR/PR/SD) were predictors of longer OS. Conclusion: SIRT is effective treatment for unresectable HCC. The lack of bilobar disease prior to SIRT and tumor response (CR/PR/SD) are positive prognostic factors.

Article Details

References

1. Đào Đức Tiến (2017) Đánh giá kết quả điều trị ung thư biểu mô tế bào gan bằng phương pháp tắc mạch xạ trị với hạt vi cầu gắn Yttrium-90. Luận văn Tiến sĩ y học, Viện Nghiên cứu Khoa học Y Dược Lâm sàng 108.
2. Forner A et al (2014) Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol 11: 525-535.
3. Güney İB (2017) HCC locoregional therapies: Yttrium-90 (Y-90) selective internal radiation therapy (SIRT). Journal of Gastrointestinal Cancer 48(3): 276-280.
4. Kolligs FT et al (2015) Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma. Liver Int 35(6): 1715-1721.
5. Lencioni R, Llovet J (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Seminars in Liver Disease 30(01): 52-60.
6. Llovet JM et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390.
7. Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37(2): 429-442.
8. Mantry PS et al (2017) Selective internal radiation therapy using yttrium-90 resin microspheres in patients with unresectable hepatocellular carcinoma: A retrospective study. J Gastrointest Oncol.
9. Mazzaferro et al (2013) Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: A phase 2 study. Hepatology 57(5): 1826-1837.
10. Meyer C et al (2017) Yttrium-90 radioembolization of unresectable hepatocellular carcinoma - a single center experience. OncoTargets and Therapy, Volume 10: 4773-4785.
11. Ozkan ZG et al (2015) Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis. Cancer Biotherapy and Radiopharmaceuticals 30(3): 132-138.
12. Pitton et al (2014) Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma. CardioVascular and Interventional Radiology 38(2): 352-360.
13. Sangro B, Inarrairaegui M, Bilbao JI (2012) Radioembolization for hepatocellular carcinoma. J Hepatol 56: 464.
14. Sangro B et al (2011) Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 54: 868-878.
15. Saxena A et al (2014) Yttrium-90 radioembolization is a safe and effective treatment for unresectable hepatocellular carcinoma: A single centre experience of 45 consecutive patients. International Journal of Surgery 12(12): 1403-1408.
16. Salem R et al (2011) Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 140(2): 497-507.
17. Sirtex (2017) SIR-spheres® Y-90 resin microspheres substantially improves quality of survival in primary liver cancer. New Study against Standard Treatment Shows.

Article Sidebar

PDF (Tiếng Việt)
Published
Jul 5, 2019
Issue
Volume 14 - No 4/2019
Section
Articles
How to Cite
Nguyen VanT., Thai DoanK., Trinh XuanH., Tran Thi AnhT., Dinh TruongG., Nguyen Thi PhuongL., Nguyen XuanQ., Nguyen Thi HuyenT., Ha MinhT., Tran VanT., Dinh ThiN., Dao DucT., & Nguyen TienT. (2019). Results of selective internal radiation therapy with SIR-Spheres for treatment of unresectable hepatocellular carcinoma . Tạp Chí Y Dược lâm sàng 108, 14(4). Retrieved from https://tcydls108.benhvien108.vn/index.php/YDLS/article/view/57